51 results about "Stem cell factor" patented technology

The disclosure relates to antibodies and antigen-binding fragments thereof that bind to Stem Cell Factor (SCF). The antibodies and antigen-binding fragments thereof specifically bind to SCF248. The disclosure further relates to methods for making the antibodies, and to methods of use of the antibodies including methods of treatment for inflammatory and / or fibrotic diseases and disorders.

The invention belongs to the technical field of medicines, and particularly relates to a gynecological postoperative wound nursing dressing and a preparation method thereof. The wound surface nursing dressing after the gynecologic operation is prepared from the following components in percentage by mass: 0.002 to 0.004 percent of stem cell factor freeze-dried powder, 0.005 to 0.01 percent of phosphoethanolamine, 0.05 to 0.1 percent of cecropin antibacterial peptide, 0.03 to 0.08 percent of aralia elata acid, 2 to 6 percent of carboxymethyl chitosan, 0.1 to 0.5 percent of polyethylene glycol, 0.5 to 1.5 percent of glycerol and the balance of water. The wound dressing not only can inhibit the growth of harmful bacteria, but also does not influence the growth of beneficial bacteria such as lactobacillus, is beneficial to the stabilization and regulation of genital tract micro-ecology, creates a healthier and more stable environment for wound healing, plays a role in the wound repairing process, accelerates wound healing and shortens the treatment time.

The present invention relates to the field of biotechnology, and in particular to an oral stem cell factor preparation and a preparation method thereof. The preparation method of the oral stem cell factor preparation comprises the following steps: (1) adding mussel mucin to a stem cell factor concentrate and mixing evenly; (2) adding synephrine to the mixture of step (1), and freeze-drying to obtain the product. The present invention innovatively adds mussel mucin and synephrine components to the stem cell factor concentrate. Among them, the synergistic effect of mussel mucin and synephrine can effectively maintain the activity of stem cell factor. The preparation method provided by the present invention has simple steps, and the obtained oral stem cell factor preparation can not only improve insulin secretion, but also has anti-inflammatory effect.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

Novel methods for producing self-renewing erythroblasts (SREs) from induced pluripotent stem cells (iPSCs) or CD34+ cells are provided. Also provided are genetically modified iPSCs or CD34+ cells having a constitutively active stem cell factor (SCF) receptor and a constitutively active Janus kinase 2 (JAK2) that can differentiate into enucleated red blood cells, self-renew, and expand in culture media for an extended period of time. In particular, the disclosed methods completely eliminate the need for SCF and Epo.

The disclosure relates to pharmaceutical formulations and method of using chymase inhibitors for the prevention and treatment of mast cell-related disease states in which chymase is involved. More particularly the present disclosure is in the field of treating or preventing or reducing the symptoms of mast cell-related diseases, including atopic dermatitis (AD), chronic urticaria (CU), Eosinophilic Gastrointestinal Disorders (EGIDs), and prurigo nodularis (PN), using a chymase inhibitor, including a chymase inhibitor that prevents cleavage of stem cell factor (SCF) and its interaction with receptor tyrosine kinase (c-kit), thereby reducing mast cell activation and proliferation.

The present invention provides a cell population and a method for obtaining the same. The cell population of the present invention is obtained by culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a culture medium containing four or less factors selected from stem cell factor, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor, and serum.

The present invention provides a culture medium and a culture method for primary human acute myeloid leukemia cells. The primary acute myeloid leukemia cell culture medium of the present invention comprises a glutamine additive, non-essential amino acids, human interleukin-6, human interleukin-7, human interleukin-3, recombinant human FLT3Ligand, recombinant human macrophage colony-stimulating factor, and human stem cell factor. Using the culture medium and culture method of the present invention, acute myeloid leukemia cells can be cultured with higher amplification efficiency and longer in vitro culture time. The present invention also provides a method and application for human primary acute myeloid leukemia cells cultured in vitro using the culture medium for use in drug efficacy evaluation and screening.

The present application provides novel anti-TSLP and anti-SCF antibodies, and binding domains thereof, as well as bispecific constructs comprising such antibodies and binding domains. The present application also provides treatment of immune response (e.g., immune response) via interaction (e.g., binding) of TSLP and / or SCF with its receptors (e.g., TSLPR and / or c-Kit, respectively) on immune cells by administering to a patient in need thereof the antibodies (or antigen binding fragments thereof), bispecific constructs or compositions described herein, or compositions. Immune cell migration, activation and / or proliferation) related disorders, such as disorders of the immune system.

The invention relates to the field of medicines, in particular to a stem cell factor composite medicine composition for treating allergic dermatitis and a preparation method thereof. The composite pharmaceutical composition is prepared from the following raw materials in parts by weight: 5 to 10 parts of stem cell factors, 2 to 6 parts of agilawood extract, 1 to 3 parts of forskolin and 0.1 to 0.3 part of stabilizer. The pharmaceutical composition can effectively inhibit bacteria, relieve pain and relieve itching, and can remarkably relieve itching and inflammation caused by allergic dermatitis by inhibiting release of inflammatory factors.

A method of differentiating pluripotent stem cells into hemangioblasts comprising incubating the pluripotent stem cells in a first serum-free differentiation medium comprising bone morphogenetic protein 4 (BMP4), vascular endothelial growth factor (VEGF) and stem cell factor (SCF) to induce differentiation of the pluripotent stem cells into hemangioblasts or hemangioblast-containing embryoid bodies is provided. The hemangioblasts or embryoid bodies may be cultured in a second differentiation medium comprising at least granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF) and interleukin-3 (IL-3) for a period of time sufficient to generate alveolar-like macrophages.

The present invention relates to compositions comprising transmembrane stem cell factor (tmSCF) polypeptide embedded in a lipid vesicle and methods of use thereof. In some embodiments, the lipid vesicle is a nanocarrier. Disclosed herein is a method for promoting angiogenesis in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a tmSCF polypeptide embedded in a lipid vesicle. Disclosed herein is a method for treating a subject with peripheral vascular disease (PVD), comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a tmSCF polypeptide.

The invention discloses a culture medium for rapid production of DC cells and application of the culture medium, and belongs to the technical field of immune cell production. The culture medium for rapid production of DC cells contains interleukin-4 (IL-4), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-15 (IL-15) and stem cell factor (SCF), is used for rapid production of DC cells, and can be used for rapid production of DC cells through culture for about 65 hours by taking mononuclear cells from peripheral blood as starting materials. According to the method, the high-purity and high-functionality DC cells are rapidly and efficiently generated, the induction time is short, and the cell purity and functionality are remarkably improved.

A hematopoietic stem cell (HSC) proliferation medium includes a basal medium, 0.1 ng / mL to 200.0 ng / mL of thrombopoietin (TPO), 0.1 ng / mL to 200.0 ng / mL of stem cell factor (SCF), 0.1 ng / mL to 20.0 ng / mL of interleukin-3 (IL-3), 0.1 ng / mL to 100.0 ng / mL of interleukin-6 (IL-6), 0.1 ng / mL to 200.0 ng / mL of Flt-3 ligand (FL), 0.1 μg / mL to 20.0 μg / mL of insulin, 0.1 μg / mL to 120.0 μg / mL of transferrin, 0.1 g / L to 3.0 g / L of human serum albumin (HSA), 0.1 μM to 4.0 μM of pyrimido-indole derivative UM729, and 0.1 μM to 2.0 μM of aryl hydrocarbon receptor (AhR) antagonist StemRegenin 1 (SR1). Methods for in vitro proliferation of hematopoietic stem cells (HSCs) and in vitro production of hematopoietic progenitor cells (HPCs) using the HSC proliferation medium are also provided.

The present invention relates to a mouse SCF-neutralizing antibody and uses thereof. Specifically, the present invention relates to an antibody for neutralizing mouse SCF, comprising a heavy and a light chain of specific sequences, or an antigen-binding fragment thereof. A novel antibody is constructed for neutralizing SCF to inhibit SCF / c-kit signaling, leading to the development of a therapeutic agent for inhibiting abnormal angiogenesis, suppressing differentiation, proliferation, and degranulation of mast cells, and restraining proliferation of smooth muscle cells.

The invention discloses an application of a soybean nuclear stem cell factor coding gene GmNSN1. The invention discloses application of the soybean nuclear stem cell factor coding gene GmNSN1 shown in SEQ ID NO.1 in genetic engineering transformation of the resistance of soybeans to prodenia litura. By mutating the gene, the resistance of soybeans to prodenia litura can be remarkably improved. The soybean nuclear stem cell factor coding gene GmNSN1 can be transformed into soybean through construction of a gene editing carrier and genetic engineering, the GmNSN1 gene is subjected to directional mutation, and the resistance of soybean to prodenia litura is regulated.

The present invention provides a culture medium and a culture method for primary human acute lymphoblastic leukemia cells. The acute lymphoblastic leukemia cell culture medium of the present invention comprises a glutamine additive, non-essential amino acids, recombinant human FLT3 ligand, human interleukin-3, human interleukin-7, human interleukin-2, human stem cell factor, and human thrombopoietin. Using the culture medium and culture method of the present invention, acute lymphoblastic leukemia cells can be cultured with higher amplification efficiency and longer in vitro culture time. The present invention also provides methods and applications for using the culture medium to culture primary human acute lymphoblastic leukemia cells in vitro for drug efficacy evaluation and screening.

The present invention provides an oral formulation for activation of autologous stem cell, comprising a stem cell activator encapsulated into a water-in-oil-in-water (W / O / W) multiple emulsion; wherein the stem cell activator induces autologous CD34+CD45+ hematopoietic stem cells (HSCs), wherein the stem cell activator is selected from the group consisting of granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF) and combination thereof. The W / O / W multiple emulsion protects the stem cell activator from stomach acid digestion, preserving its bioactivity during transport to the bone marrow (BM) via the Peyer's patches of the intestinal lymphatic system.

A nasal allergen blocking agent. Specifically, the present invention relates to a preparation method for an allergen blocking agent loaded with an umbilical cord mesenchymal stem cell culture medium extract. The provided allergen blocking agent is prepared from the following raw materials: lyophilized powders of the umbilical cord mesenchymal stem cell culture medium extract, hydroxypropyl methylcellulose, a honeysuckle extract, and borneol. By means of adding the honeysuckle extract and the umbilical cord mesenchymal stem cell culture medium extract to the allergen blocking agent, under the interaction of various raw materials, capillary permeability can be reduced by means of dilating capillaries, thereby reducing tissue fluid exudation, helping reduce swelling, inhibiting smooth muscle contraction, alleviating the spasticity in the respiratory tract and other parts, and improving related discomfort symptoms. The dry powder mixture is loaded into a nasal spray reagent bottle for use. The anti-allergen blocking agent can not only physically isolate allergens, but also load a variety of stem cell factors contained in the umbilical cord mesenchymal stem cell culture medium extract, thereby eliminating chronic nasal mucosa inflammation, repairing nasal mucosa damage without any toxic and side effects, and effectively resisting the onset of allergic rhinitis.

The present disclosure provides immunodeficient NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ (NSG TM ) mouse models comprising an inactivated mouse Flt3 allele, a nucleic acid encoding human interleukin 3 (IL3), a nucleic acid encoding human granulocyte / macrophage stimulating factor (GM-CSF), a nucleic acid encoding human stem cell factor (SCF), and an HLA-A2 / H2-D / B2M transgene encoding (i) human B2 microglobulin (B2M) covalently linked to the MHC class I, alpha 1 and alpha 2 binding domains of the human HLA-A2.1 gene and (ii) the alpha 3 cytoplasmic and transmembrane domains of murine H2-Db.

This disclosure is based, at least in part, on the unexpected discovery that genetically modified pluripotent stem cells having a constitutively active stem cell factor (SCF) can differentiate into enucleated red blood cells, self-renew, and expand in culture media for an extended period of time. Accordingly, the disclosed methods enable large-scale production of red blood cells with significantly reduced overall cost as compared to the existing methods.

Novel methods of creating personalized mesenchymal stem cells from pluripotent stem cells, including the utilization of extracellular matrix components, optionally seeded with exogenous differentiation factors for creation of a substrate for promotion of mesenchymal stem cell formation from pluripotent cell populations. Matrices useful for stimulation of differentiation include decellularized bone matrix, placental matrix, and adipose tissue derived matrix. Growth factors such as BMP2, BMP4, GDF-11, and stem cell factor can be added to said matrix. Stimulation of differentiation can be induced by exposure to conditioned media isolated from mesenchymal stem cells.

The invention discloses a prostate cancer organoid culture medium and a culture method thereof, and particularly relates to the technical field of prostate cancer organoid culture, and the prostate cancer organoid culture medium comprises a basic culture medium and the following components: 20-100ng / ml of epidermal growth factors, 20-100ng / ml of prostate cancer organoid and 20-100ng / ml of The concentration of Noggin is 50 to 500 ng / ml; the concentration of R-spondin is 50 to 500 ng / ml; the weight of Wnt3a is 50 to 500 ng / ml; the concentration of FGF is 101 to 50ng / ml; 1 to 50 ng / ml of FGF (fibroblast growth factor); stem cell factors are 1 to 50 ng / mL; the concentration of antibiotics is 50-500 ng / ml; dHT is 1 to 50 ng / ml; the method comprises the following steps: 1, obtaining a prostate cancer tissue sample, placing the prostate cancer tissue in a sampling bottle containing a tissue preservation solution at 2-8 DEG C, and rapidly transferring the prostate cancer tissue to a clean laboratory for subsequent treatment; 2, preparing a plurality of culture dishes, adding a 4 DEG C precooled prostate cancer organoid culture buffer solution for later use, disinfecting a sampling bottle, putting the tissue into the culture dishes, and cleaning the tissue for three times by using the prostate cancer organoid culture buffer solution; the culture medium and the culture method provided by the invention can promote the growth of organs with prostatic cancer, so that the culture medium has a better actual use effect and is convenient to popularize and use.

The invention relates to the technical field of stem cell culture. The invention provides a stem cell three-dimensional culture medium and application thereof. The culture medium comprises a basic culture medium and an additive, the additives comprise collagen, Pluronic F-68, hyaluronic acid, folic acid, basic fibroblast growth factors, linoleic acid, arachidonic acid, platelet-derived growth factors, epidermal growth factors, insulin-like growth factor-1, SCF stem cell factors, thrombopoietin, vitamin C, vitamin E, vitamin B1, vitamin B2 and vitamin B6. The culture medium provided by the invention does not need a three-dimensional carrier, and stem cells can be directly cultured in a suspension culture mode. Meanwhile, cell adherence can be effectively prevented, collagenase is not needed in subsequent treatment, the in-vitro culture amplification speed and the cell survival rate are further increased, and the method is suitable for large-scale production and preparation of stem cells.

The disclosure relates to methods for treating atopic dermatitis with an antibody that binds to stem cell factor 248 (SCF248).

The utility model discloses a packaging bag for autologous stem cell factor culture, which comprises an autologous stem cell factor culture bag, the left side of the outer surface of the upper end of the autologous stem cell factor culture bag is fixedly provided with a liquid injection valve, and the right side of the outer surface of the upper end of the autologous stem cell factor culture bag is fixedly provided with a liquid guide pipe. A handle is fixedly mounted on the outer surface of the lower end of the autologous stem cell factor culture bag. According to the packaging bag for autologous stem cell factor culture, the protection assembly is arranged, the autologous stem cell factor culture bag can be protected through the arranged buffer air column, the damage probability of the autologous stem cell factor culture bag is reduced, the protection assembly is arranged, and the autologous stem cell factor culture bag can be protected through the buffer air column. The first plastic block and the second plastic block in the protection assembly can be opened, and after the first plastic block and the second plastic block are opened, the situation in the autologous stem cell factor culture bag can be conveniently observed through the autologous stem cell factor culture bag.

Embodiments of the disclosure include systems, methods, and compositions for producing megakaryocytes and platelets for recipient individuals in need thereof. In certain embodiments the megakaryocytes and platelets may be produced following co-culture of MSCs and CD34+ cells in media comprising stem cell factor, thrombopoietin, IL-6, IL-3, FLT3-ligand, and an inhibitor of Rho associated coiled – coil containing protein kinase (ROCK).

The invention discloses a targeted delivery preparation as well as a preparation method and application thereof, and belongs to the technical field of biology and new medicine. The targeted delivery preparation comprises an agent A and an agent B in a ratio of (0.1-0.3) g: (2-5) mL; the agent A comprises nasal brain targeting peptide modified stem cell factor liposome freeze-dried powder and gel dry powder, the amino acid sequence of the nasal brain targeting peptide is as shown in SEQ ID NO.1, and the gel dry powder is formed by self-crosslinking mangiferin and rutin; and the agent B is a normal saline solution containing carboxymethyl chitosan. The targeted delivery preparation not only can meet long-time stable storage, but also can enhance the nasal-brain delivery efficiency of stem cell drugs. Besides, the targeted delivery preparation can be used independently or in combination with other treatment drugs, and is used for treating ischemic cerebral diseases, especially cerebral arterial thrombosis.

The invention relates to the technical field of sperm cryopreservation, in particular to an efficient sperm freeze-drying preservation solution and a preparation method thereof. The efficient sperm freeze-drying preserving fluid is prepared from the following components in percentage by weight: 0.06%-0.1% of amino trimethylolmethane, 0.06%-0.1% of amino trimethylolmethane, 0.02%-0.04% of citric acid, 1%-2% of lecithin, 2%-5% of vitamin C, 8%-15% of trehalose, 3%-5% of mannitol, 10%-20% of polyvinylpyrrolidone, 0.3%-0.4% of disodium EDTA (Ethylene Diamine Tetraacetic Acid), 3%-5% of fetal calf serum, 20%-25% of dimethyl sulfoxide and the balance of water. 20-25% of a phosphate buffer solution and 0.05-0.1% of stem cell factors; the sperm freeze-drying agent can protect sperms in the freeze-drying process, reduce sperm apoptosis in the freeze-storage process, enhance the adaptability of the sperms to the freeze-storage environment, help the sperms to recover activity and functions after unfreezing, effectively improve the survival rate and activity of the sperms after freeze-drying and resuscitation, reduce oxidative stress reaction caused by freezing and improve the survival rate of the sperms after freeze-drying and resuscitation. The cryopreserved sperm freeze-drying agent can improve the quality of cryopreserved sperms, improve the vitality and fertilization ability of the cryopreserved sperms, is suitable for a freeze-drying method, and enables the sperms to be transported and stored in a room temperature environment.